250 results about "Nervous system disease" patented technology

The invention discloses a nervous system disease auxiliary evaluation method based on a large model and related equipment. The method comprises the following steps: constructing a structured knowledge graph based on multi-modal heterogeneous data of nervous system disease guide texts, symptom descriptions and examination results; a graph neural network module is embedded based on the structured knowledge graph in combination with a large language model, an inference network model of a dynamic graph structure is generated, and a dynamic diagnosis path tree is formed by calculating the relation weight between the medical nodes in the graph; and generating interpretable diagnosis suggestions through the reasoning network model according to the current symptom description, the examination result and the historical medical history of the patient. The problems that an existing model still has obvious bottlenecks and clinical challenges, depends on single modal data, is insufficient in quantification of dynamic signs such as a reasoning level, tremor frequency and gait abnormity, does not achieve disease development time sequence modeling and is difficult in clinical conversion can be solved.

The invention relates to a device for risk assessment of nervous system diseases, and a processor of the device is configured to receive eye movement data and electroencephalogram data which are associated in a time sequence, and fuse a double-branch deep neural network in a model through multiple modes to assess the risk of the nervous system diseases, performing feature extraction and attention mechanism-based cross-modal feature fusion on the eye movement data and the electroencephalogram data to obtain cross fusion features; and outputting risk assessment results and risk assessment parameters of at least one type of nervous system diseases through an output layer of the multi-modal fusion assessment model. According to the method and the device, the problem that diagnosis sensitivity and universality are insufficient due to the fact that diagnosis only depends on a single information source in related technologies is solved, disease features can be more comprehensively constructed from two levels of neural activity and behavior response by fusing data of two modes of eye movement and electroencephalogram, parallel diagnosis is further performed for multiple types of diseases, and the diagnosis efficiency is improved. The sensitivity and applicability of neuropsychiatric diagnosis are improved, and particularly, the method has more remarkable accuracy in early stages such as mild cognitive impairment and the like.

The invention belongs to the technical field of drug development, and particularly relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of a medicine for treating nervous system diseases. It is proved that the compound 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The invention belongs to the technical field of drug development, and particularly relates to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide in preparation of a medicine for treating nervous system diseases, in particular to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide. It is proved that the compound (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.

The invention relates to the technical field of digital medical treatment, and particularly discloses an artificial intelligence diagnosis system for nervous system diseases. The system comprises a data acquisition module, a preprocessing module, a multi-modal feature extraction module, a feature fusion module, a disease classification module, an interpretability analysis module and a doctor feedback and model updating module. The system supports acquisition and fusion of medical images, electroencephalogram signals, biochemical indexes, questionnaire information and wearable device data, constructs unified feature representation through a weighted attention mechanism, and outputs a prediction result of nervous system diseases based on a deep learning model. And meanwhile, the system is combined with a Shapley value method to realize the interpretability of the diagnosis process, and supports closed-loop return of doctor feedback information and model increment updating. The nervous system disease diagnosis accuracy and early recognition capability are improved, and the method has relatively high clinical deployability and adaptive optimization capability.

The application relates to the field of medicine weighing, in particular to a medicine weighing device for treating nervous system diseases in traditional Chinese medicine, which comprises a supporting seat, a weighing assembly is arranged at the upper end of the supporting seat, a medicine collecting assembly is arranged at the lower end of the supporting seat, a medicine containing assembly is arranged at the upper end of the weighing assembly, a shielding assembly is arranged at the upper end of the supporting seat, the weighing assembly comprises four pressure sensors, the four pressure sensors are fixedly connected to the upper surface of the supporting seat, grooves are arranged on the upper surface of the supporting seat, the four pressure sensors are clamped in the grooves, the fixed bars are driven to move downwards by two air cylinders, the fixed bars drive the shielding columns to move downwards when moving downwards, the shielding columns drive the conical blocks at the upper end to be pulled out from the clamping holes, the through holes and the lower ends of the round holes in sequence, at this moment, the medicine in the conical disc falls along with the clamping holes and the through holes, so that the medicine falls in the medicine disc along the conical blocks, the falling medicine is shielded and protected by the cylinder, and the medicine is prevented from being polluted.

Provided is a polypeptide which contains a polypeptide having at least 80%, 85%, 90%, 95%, or 99% identity to amino acid sequence MTYRPGYNPFG (SEQ ID NO: 41) or amino acid sequence AKGYYRPYGVPV (SEQ ID NO: 22), or a polypeptide having one or more amino acid substitutions, deletions and / or additions relative to the amino acid sequence as shown in SEQ ID NO: 41 or 22. The provided polypeptide can interfere with the binding of a Brag2 synaptic protein to the C terminus of an AMPA receptor, thereby inhibiting NMDA-mediated excessive endocytosis of an AMPA receptor and neuronal apoptosis, and playing a role in protecting neuronal cell activity. Therefore, the polypeptide has application prospects and potential development values as a drug for treating nervous system diseases such as strokes, depression, Alzheimer's disease and drug addiction.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior and posterior segment ocular diseases or disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases or disorders.

The invention discloses application of a propanamide derivative in preparation of a medicine for treating nervous system diseases, and belongs to the technical field of medicines, and the propanamide derivative is N-[(6-methoxy-1H-benzimidazole-2-yl) methyl]-3-(pyridine-3-yl) propanamide. The invention discloses the neuroprotection application of the propanamide derivative for the first time by adopting the propanamide derivative to prepare a medicine for treating nervous system diseases, and the protection efficacy of the propanamide derivative is equivalent to that of a positive medicine MK-801.

The application discloses oripramine derivatives, a preparation method and pharmaceutical compositions and application thereof, wherein the oripramine derivative is a compound with the shown structure or a medicinal salt thereof, wherein R is selected from any one of hydrogen, deuterium and substituted or unsubstituted alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl. Experiments prove that the oripramine derivative has higher anti-inflammatory activity and lower toxicity compared with existing oripramine, can be applied as an active ingredient in the preparation of an anti-inflammatory disease, a nervous system disease or an antitumor drug, provides a new thought and method for preparing a novel oripramine derivative drug with better curative effect and lower toxicity, and has a wide application prospect.

1. The name of the design product: ultrasonic therapeutic instrument. 2. The use of the design product: for the auxiliary treatment of cardiovascular and cerebrovascular diseases, soft tissue contusion, and nervous system disease rehabilitation. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view 1.

To provide a method for treating a GLP-1 / GLP-1 1R related disease such as a carbohydrate metabolism disorder-related disease, a fat metabolism disorder-related disease, or a GLP-1 / GLP-1 1R related nervous system disease, and to provide a medicament.SOLUTION: Provided is a method for treating a disease by regulating GLP-1 / GLP-1 1R, comprising administering an effective amount of GLP-1 to a subject.SELECTED DRAWING: None

The invention discloses a construction method of a conditional knock-down dynactin animal model of astrocytes and an application of the animal model of the conditional knock-down dynactin animal model of the astrocytes. According to the method, a Dctn1LoxP gene knock-in mouse is hybridized with an Aldh1l1-Cre / ERT2 transgenic mouse, a target genotype mouse is obtained through three rounds of breeding, 100mg / kg Tamoxifen is continuously injected into the intraperitoneal cavity of the 2-month-old mouse for 5 days, and specific knock-down of dynactin in brain and spinal astrocytes is realized, including knockout of p150Glue and reduction of DCTN4, p50 and Arp1alpha protein levels. The model has the advantages of being high in specificity, permanent in intervention aging and capable of covering multiple life stages, the defects of a traditional model are overcome, the model can be used for researching the influence of dynactin on astrocyte neurobiological functions, a reliable tool is provided for screening related targets of nervous system diseases, and the model has important application value.

In various aspects of the present disclosure, there is provided a method of detecting, preventing, reversing, treating, or delaying the onset of a nervous system disease (e.g., an adult onset nervous system disease, Alzheimer's disease, Parkinson's disease, frontotemporal dementia).

This invention relates to the field of pharmaceutical science, and more particularly to the application of NAT10 antagonists in the preparation of medicaments for the prevention and / or treatment of epilepsy. This invention provides the application of NAT10 antagonists in the preparation of medicaments for the prevention and / or treatment of neurological diseases characterized by epileptic seizures. This invention is the first to demonstrate through pharmacological experiments that a NAT10 antagonist, remodelin, has anti-epileptic effects, thus possessing high clinical application value and development prospects.

The invention provides a construction method and application of a humanized MECP2 gene mouse model, and relates to the field of gene engineering. The model animal with the humanized hMECP2 gene is successfully prepared, the humanized hMECP2 protein can be normally expressed in the body of the model, and the model can be used for MECP2 gene function research and screening and evaluation of human MECP2 targeted drugs and therapies. The animal model prepared by the invention can be used for rapidly establishing more different MECP2 mutation humanized disease mouse models, and is applied to drug screening, drug effect research, related nervous system disease and tumor treatment and the like aiming at human MECP2 target sites, so that the research and development process of new drugs is accelerated, the time and the cost are saved, and the drug development risk is reduced. And a powerful tool is provided for researching the functions of the MECP2 protein and screening drugs.

This invention discloses an alkaloid compound and its uses. Specifically, the invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I), and also to pharmaceutical compositions comprising said compounds and their uses. In particular, this alkaloid compound has a significant inhibitory effect on angiogenesis and can be used as a medicament for the prevention or treatment of tumors, inflammation, ophthalmic diseases, abnormal fibrosis or scar formation, cardiovascular and cerebrovascular diseases, nervous system diseases, infectious diseases, metabolic diseases, and diseases related to abnormal angiogenesis in mammals.

The present invention addresses the problem of providing a suppressant for nervous system vascular barrier breakdown. Provided is a suppressant for nervous system vascular barrier breakdown, the suppressant comprising (a) or (b) as an active ingredient: (a) an enzyme capable of specifically detaching or decomposing a sugar chain of low-glycosylated basigin; and (b) an antibody, an aptamer, or a lectin that specifically binds to low-glycosylated basigin and suppresses the nervous system vascular barrier breakdown caused by basigin.　Preferably, the sugar chain of the low-glycosylated basigin is high-mannose sugar chain.

The present invention relates to a composition for preventing or treating bladder diseases, a composition for preventing or treating neuropathic pain, neuroinflammation or inflammatory skin diseases, or the therapeutic use of a novel compound YJ102, the compound YJ102 of the present invention inhibits neuropathic pain due to various reasons, ameliorates urination disorders due to spinal cord injury, restores bladder hypertrophy and bladder function, inhibits erythema and keratinogenesis, which are main symptoms of psoriasis, in a psoriasis animal model, and has a superior effect than conventional drugs. The composition can inhibit increase of the thickness of the epidermal layer and spleen hypertrophy caused by psoriasis, and can be used for treating various difficult nervous system diseases or bladder diseases.

The present invention relates to polymorphs of a nitrogen-containing heterocyclic compound. The polymorphs of the present invention can effectively enhance or reactivate synaptic plasticity, and inhibit or eliminate the accumulation of beta-amyloid, without causing side effects, thereby exerting a therapeutic effect on various nervous system diseases or neurodegenerative diseases. In addition, the polymorphs of the present invention exhibit excellent physicochemical properties, such as stability, solubility, hygroscopicity, and mechanical strength, and show excellent permeability to the blood-brain barrier (BBB).

The utility model relates to a detection kit of autoimmune nervous system disease, including box and with box rotation connection's box cover, the inside position adjustable of box is provided with a plurality of baffle, the both sides of each baffle upper portion respectively symmetry is provided with a plurality of clamping block, moves the baffle, makes the clamping block between adjacent two baffles clamp test tube, each baffle top is equipped with the limiting structure for fixing its position, the inside one side of box evenly interval is provided with a plurality of card slot, the baffle one side has opened first recess, and the baffle upside has opened the second recess with first recess intercommunication, the limiting structure includes the clamping block for with first recess sliding fit and with clamping block vertical connection's operating block, the operating block is away from the inner wall between second recess between clamping block one side and first recess and is equipped with the compression spring. The detection kit of autoimmune nervous system disease can clamp test tube of different diameter size, and the scope of application is wider.

The invention discloses a sparse electroencephalogram signal source positioning method based on functional magnetic resonance guidance, and relates to the crossing field of electroencephalogram signal processing and neuroimaging technologies. The method mainly comprises three parts of fMRI-guided sparse source space construction, subject specificity forward model construction and multi-target regularization inverse problem solving. The method comprises the following steps: firstly, screening high-activation voxels through BOLD signal intensity of fMRI, and constructing a sparse source space through connected component analysis and representative point selection; then, a subject specific boundary element (BEM) head model is constructed based on the structural MRI, and electrode registration and lead field matrix calculation are completed; and then a multi-target regularization model fusing data fidelity, space compactness and intensity consistency is constructed, optimal estimation of source current intensity is obtained through analysis and solution, and finally a positioning result of brain power activation is output. According to the method, the advantages of high time resolution of the EEG and high spatial resolution of the fMRI are fully played, the limitations of inverse problem morbidity, low spatial resolution and insufficient multi-mode fusion in traditional brain power supply positioning are effectively solved, and brain power supply positioning with high precision, noise resistance and high interpretability is realized; and a new scheme is provided for cognitive neuroscience research, nervous system disease diagnosis and brain-computer interface development.

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system diseases. Pharmaceutical compositions and methods of making various benzisoxazole and benzisothiazole compounds are provided. These compounds are considered to be modulators of the serotonin 2A (5-HT2A) receptor.

Provided herein are bilobalide derivative compounds, processes for their preparation, methods of use, and uses for the prevention or treatment of nervous system diseases and cancer.

The present application relates to an organic compound having mTOR inhibitory activity, a preparation method therefor, a pharmaceutical composition comprising the organic compound, and a use thereof for the treatment or prevention of a disease responsive to mTOR inhibition. In particular, the compound of the present invention can be used in the treatment of a disease responsive to mTOR inhibition or a condition requiring mTOR inhibition, such as cancer, a nervous system disease, a metabolic disease, an autoimmune disease, or organ fibrosis, or can be used as an immunosuppressant.

The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and an application thereof as a GABAA receptor regulator in treatment of depression, convulsions, Parkinsonism and nervous system diseases.

The invention provides a method for preventing or treating diseases related to CSNK2B gene deletion. The disclosure also provides a CSNK2B protein or a variant thereof, a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, an expression cassette comprising a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, a vector comprising a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, a virus, such as an AAV particle, expressing a CSNK2B protein or a variant thereof, and a method for preparing the CSNK2B protein or a variant thereof. According to the present invention, the use of the cells expressing the CSNK2B protein in the preparation of drugs for treating or preventing CSNK2B gene deletion-related diseases in subjects is provided, and the CSNK2B gene deletion-related diseases are selected from the group consisting of Rett syndrome, autism spectrum disorder (ASD), Porier-Bienvenu neurodevelopment syndrome (POBINDS), epilepsy or broad-spectrum development retardation, or the use of the cells expressing the CSNK2B protein in the preparation of the drugs for treating or preventing the CSNK2B gene deletion-related diseases in the subjects,

The invention discloses application of a Kunlun chrysanthemum aqueous extract in preparation of drugs for improving autism core symptoms, and belongs to the technical field of biological medicines. In order to solve the problem that the prior art lacks a medicine which is small in side effect, natural in source and capable of improving the autism core symptom, the invention provides application of a coreopsis tinctoria aqueous extract in preparation of the medicine for improving the autism core symptom, and the coreopsis tinctoria aqueous extract has a multi-dimensional synergistic effect of adjusting synaptic plasticity, inhibiting neuroinflammation, improving behavioral phenotype and the like. The concept of treating complex nervous system diseases by traditional Chinese medicine is met, and the autism core symptom is fundamentally improved; the medicine containing the coreopsis tinctoria aqueous extract provided by the invention has the advantages of high safety and small side effect.